[농업경제신문 임해정 기자] To slow the spread of the highly contagious delta mutation, Israel eventually approved a third dose of the Pfizer vaccine before FDA approval.
Israel will begin the world’s first third dose of Pfizer’s COVID-19 vaccine to people over the age of 60, according to Reuters.
Channel 13 TV and Cannes Public Radio reported that eligible people could get a booster dose if they got their second dose more than five months ago.
Israel has been a global leader in immunization rollouts, with many older adults getting vaccinated in December, January and February as they were considered the most vulnerable segment of the population.
However, since the advent of the delta mutation, the Ministry of Health reported twice that the effectiveness of the vaccine against infection and protection against severe disease decreased slightly.
A Pfizer official said on Wednesday that people think they need a booster shot to maintain protection against the coronavirus.
It also said it could apply for FDA emergency approval for additional injections as early as August.
The media reported that Israel’s health minister ordered a third injection to health maintenance groups after Israeli experts approved the campaign late Wednesday.
Last week, the Ministry of Health estimated that the vaccine was only 41% effective at preventing symptomatic infections in the past month. Protection against severe disease was strong at 91%.
About 57% of Israel’s 9.3 million population have been vaccinated. About 160 people are hospitalized with severe symptoms, and the number of daily infections has soared from just a few a day a few months ago to more than 2,000.
According to a previous study by Canadian and British health authorities, Moderna was 72% effective against delta mutations and Pfizer was 36% with a single dose. However, when two doses of Pfizer were inoculated, the protection against the delta mutation increased to 88%.
Pfizer vaccine is a messenger ribonucleic acid (mRNA) vaccine. Pfizer-related stocks include KPXF Life Sciences, Woori Bio, Jeil Pharm, Shinpoong Pharm, and Celltrion.
In Korea, Samsung Biologics is expected to start bottling and packaging Moderna’s vaccine from the third quarter. In addition, in Korea, up to 1 billion doses are being discussed with mRNA vaccine manufacturers.
Earlier, Reuters reported that Hanmi Pharmaceutical could use it for vaccine production due to its large capacity for diabetes drugs and the stagnation of the Sanofi project, and Quratis could produce mRNA vaccines at a new plant built last year.
In the stock market on the 29th, the stock price of ST Pharm, a ribonucleic acid (mRNA)-related stock, rose 3.00% from the previous day to KRW 110,000, Enzychem Life Sciences rose 2.81% to KRW 87,700, Hanmi Science rose 0.54% to KRW 74,000, and Cellu Med rose 0.41% to 9,700 won.
However, shares of Igene fell 7.75% from the previous day to 36,900 won, Jinwon Life Sciences fell 4.42% to 44,300 won, Leeyeon Pharmaceutical fell 0.92% from the previous day to 53,600 won, and Olix fell 1.94% from the previous day. It fell to 45,600 won.
In addition, while Samyang Holdings fell, Green Cross, Nyvek, and Hanmi Pharm rose. Aminologics, Serin Bio, Pharmicell, and Olipass were the same as the day before.
On the 29th, the highest trading volume among pharmaceutical and bio stocks was Curacle, Kukjeon Pharm, Pharma Korea, Samchundang Pharm, Bifido, Hulim, Bukwang Pharm, Tium Bio, Aprogen Pharm, Cho-A Pharm, Jinwon Life Sciences, Nature Cell, Seegene, Samsung Pharm and Bioneer were named.
[알림] This article is for investment judgment reference only, and we are not responsible for any investment loss based on it.
By Lim Hae-jeong, staff reporter [email protected]